Testosterone: What to Ask About a Claim

Who may qualify?

If you used testosterone and later had a heart problem or blood clot, ask about your medical care and legal options. Your product, use dates, diagnosis and the law need a check. An injury after use does not by itself prove a claim.

Keep the product name, dose and how you took it with your care records. Tell your clinician why it was prescribed and about other medicines you used. Ask the lawyer which records can show use and harm. Mark dates you do not know instead of guessing a start date or duration.

The FDA describes approved testosterone use for men with low levels and an associated medical condition. Treatment decisions belong with a clinician, not an ad or a lawsuit page. A prescription reason is a fact to review; it does not decide all legal rights. Ask separately about your treatment and any claim.

If you are helping a relative who is ill or has died, ask what authority you need. Being a family member does not give automatic access to all health records. Tell the lawyer about the death, any prior filing and who can act for the person. Ask which time limit applies to those facts.

What could I get?

Ask about your own claim and any real offer. An old court grouping or a drug warning does not set a payment for you. Get any proposed agreement, fee and expense terms explained before signing.

Do not use a headline amount from another person’s case to plan your finances. Ask what losses can be claimed under the law and what proof is needed. Keep bills and notes about the effect of the injury on work or daily life. A lawyer can explain which parts matter to your claim.

If you already received money or signed a release, bring those papers to the review. Ask which claims and parties the agreement covers. Also ask what expenses would come out of any payment. Do not assume a new inquiry changes a prior signed agreement.

Is there a deadline?

Ask promptly about the time limit for your own claim. Bring the dates of use, diagnosis and any earlier legal papers. Do not calculate a cutoff from an old MDL number or FDA announcement.

Court guidance explains that filing limits depend on the claim and the law. A date for another state or another product may not apply to you. Ask what event starts the clock and what action is needed before the limit. A general page cannot decide that you have no legal options.

Keep the dates you first had symptoms separate from the diagnosis date. Note when you started, changed or stopped each product and what you can confirm from records. Tell the lawyer about any earlier lawsuit, release or advice you received. These facts help frame the question; they are not a way to set your own legal deadline.

What happens after I check?

First gather the product and health facts you know. Then ask which records, legal issues and time limit need review. Read the written fees and record-sharing terms before hiring a firm.

Make a short timeline for each product rather than combining all testosterone use into one line. Put prescriptions and visits beside the dates they concern. Include tests and other medicines your clinician says matter. Ask which gaps need records and which can be explained from what you already have.

Ask who would receive your files and who would represent you if you hire a firm. Ask what the next step requires and what it could cost. Keep a copy of any signed agreement. A request for records is not the same as a promise to take the case or pay money.

Questions people ask

Does the newer FDA announcement prove an older injury claim is invalid? It does not decide your individual legal rights. Ask a lawyer to check your product, use, injury and applicable law. Keep the dated warnings and any earlier legal papers for that review.

Does removal of heart-risk wording mean every boxed warning disappeared? No. The July 2025 FORTESTA label retains a boxed warning about accidental exposure to women or children. Check the warnings for the product you use instead of treating all gels alike.

How Testosterone Replacement Therapy Causes Cardiovascular Injury

Testosterone replacement therapy (TRT) products — marketed as treatments for 'Low T' — carry serious cardiovascular risks that manufacturers knew about and failed to adequately disclose. Scientific studies, including a landmark 2010 NEJM trial stopped early due to excess cardiac events, show that synthetic testosterone elevates heart attack, stroke, blood clot, and sudden cardiac death risk through multiple biological mechanisms. Men who used AndroGel, Axiron, Androderm, Testim, Fortesta, or Depo-Testosterone and suffered cardiovascular injuries may have claims against the manufacturers responsible for suppressing this evidence while aggressively marketing these drugs to millions of American men.

Polycythemia — Dangerous Blood Thickening

Testosterone powerfully stimulates erythropoiesis — the production of red blood cells — through erythropoietin signaling in bone marrow. Elevated red blood cell counts increase blood viscosity (thickness), dramatically raising the risk of thrombosis. When hematocrit rises above 54%, the risk of clot formation in coronary arteries and deep veins reaches dangerous levels. Manufacturers were required to monitor hematocrit but failed to warn prescribers of the full risk magnitude or instruct adequate monitoring intervals.

Platelet Aggregation and Thrombosis

Testosterone and its metabolites enhance platelet activation and aggregation, increasing the tendency of blood to form clots at sites of vascular injury. This pro-thrombotic effect operates independently of polycythemia, compounding overall clotting risk. Elevated androgen levels suppress natural anticoagulant pathways, creating a hypercoagulable state that predisposes users to deep vein thrombosis (DVT), pulmonary embolism (PE), and ischemic stroke — even in men with no prior clotting history.

Direct Cardiac Effects — LV Hypertrophy and Arrhythmia

Supraphysiologic testosterone levels cause pathological left ventricular hypertrophy (LVH) — thickening of the heart's main pumping chamber. LVH impairs diastolic filling, reduces cardiac efficiency, and creates an arrhythmogenic substrate. Animal and human studies demonstrate testosterone's direct cardiotoxic effects at elevated concentrations, including increased susceptibility to ventricular arrhythmias and sudden cardiac death. These structural changes may be irreversible and are distinct from the more commonly publicized thrombotic risks.

Rapid Testosterone Fluctuations from Topical Products

Transdermal gels (AndroGel, Axiron, Testim, Fortesta) and patches (Androderm) cause significant intra-day and day-to-day testosterone fluctuations. These pharmacokinetic peaks — especially immediately after application — trigger acute cardiovascular stress responses including elevated blood pressure, increased heart rate, and endothelial dysfunction. Unlike injectable testosterone which produces predictable peaks and troughs, transdermal formulations create less predictable surges. Manufacturers promoted gel products for convenience while concealing this pharmacokinetic cardiovascular risk profile.

• Age and Pre-Existing Cardiovascular Risk: Men aged 45–75 — the primary TRT marketing demographic — already carry elevated baseline cardiovascular risk from atherosclerosis, hypertension, and metabolic syndrome. The TOM Trial (2010), in older men with mobility limitations and a high prevalence of chronic disease, was stopped early after more cardiovascular adverse events occurred in the testosterone group; its authors cautioned against broader inferences. The larger TRAVERSE trial (2023) of 5,246 men aged 45–80 with pre-existing or high cardiovascular risk found testosterone gel noninferior to placebo for major cardiovascular events (7.0% vs 7.3%), with more atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group. In February 2025 FDA removed the increased-cardiovascular-outcome wording from testosterone boxed warnings.
• Low-T Marketing Targeting Borderline Testosterone Levels: The pharmaceutical industry spent hundreds of millions of dollars funding 'Low T awareness' campaigns targeting men with testosterone levels in the low-normal range who had no underlying medical hypogonadism. This expanded the exposed population far beyond men with clinical need, exposing millions of men with marginal cardiovascular risk tolerance to unnecessary TRT-associated cardiac risk. The FDA ultimately restricted approved TRT indications to documented hypogonadism from underlying medical conditions, explicitly rejecting age-related decline as a valid indication.
• Supraphysiologic Dosing and Hematocrit Monitoring Failures: Real-world prescribing — particularly through 'Low T clinics' and telehealth platforms — often resulted in supraphysiologic testosterone levels without adequate hematocrit monitoring. Standard dosing protocols assumed regular lab monitoring that frequently did not occur in clinical practice. Manufacturers knew prescribers were not following monitoring guidelines but failed to implement meaningful safeguards or strengthen monitoring warnings on labeling until forced by FDA action in 2014–2015.
• Delayed Cardiovascular Events — Discovery Rule Implications: TRT-associated cardiovascular injuries often present months to years after treatment initiation, as polycythemia and LV hypertrophy develop gradually. Many victims did not connect their heart attack, stroke, or DVT to TRT use — particularly given the 'vitality and wellness' framing of marketing. The discovery rule applies in most states, meaning the statute of limitations runs from when a plaintiff knew or should have known of the connection between TRT and their injury, not necessarily from the injury date itself.

Stroke (Ischemic and Hemorrhagic)

Stroke occurs when blood supply to part of the brain is interrupted (ischemic) or a blood vessel ruptures (hemorrhagic). Testosterone therapy's thrombogenic effects — including increased platelet aggregation and elevated hematocrit — raise stroke risk. A 2014 PLOS ONE study found a 100% increased stroke risk in younger TRT users with pre-existing heart disease.

• Sudden facial drooping on one side
• Arm weakness or numbness (one side)
• Slurred or confused speech
• Sudden severe headache without cause
• Vision disturbance in one or both eyes
• Loss of balance or coordination
• Current testosterone therapy use
• Atrial fibrillation
• Hypertension
• Prior TIA (transient ischemic attack)
• Polycythemia from TRT use
• Age over 50
• Emergency tPA (tissue plasminogen activator) for ischemic stroke
• Mechanical thrombectomy
• Blood pressure management
• Anticoagulation therapy
• Surgical intervention for hemorrhagic stroke
• Long-term physical, occupational, and speech therapy

Polycythemia (Elevated Red Blood Cell Count)

Polycythemia is an abnormal increase in red blood cells, raising blood viscosity and clotting risk. Testosterone directly stimulates erythropoiesis (red blood cell production) in bone marrow. Hematocrit levels above 54% are considered dangerous. TRT-induced polycythemia is a known adverse effect — it is listed in product labeling — but many prescribers failed to monitor hematocrit levels during therapy, allowing the condition to progress undetected and increasing cardiovascular event risk.

• Headaches and dizziness
• Blurred vision
• Redness or flushing of face and hands
• Itching, especially after hot shower
• Shortness of breath
• Fatigue and weakness
• Testosterone therapy — direct mechanism
• Injectable testosterone (highest risk form)
• Failure of physician to monitor hematocrit during TRT
• Dehydration
• Sleep apnea (exacerbates TRT-induced polycythemia)
• Discontinuation or dose reduction of testosterone therapy
• Therapeutic phlebotomy (regular blood removal)
• Hydration
• Aspirin therapy to reduce clotting risk
• Monitoring hematocrit every 3–6 months during TRT
• Switch to lower-dose formulation or alternate delivery method

Corporate Defendants in the Testosterone Therapy Lawsuit: AbbVie, Eli Lilly, Actavis & More

The testosterone therapy litigation involves multiple major pharmaceutical companies that manufactured and aggressively marketed TRT products while cardiovascular evidence mounted. AbbVie — maker of AndroGel, the highest-volume TRT product — is the primary defendant and faces the largest plaintiff docket in MDL 2545. Other defendants include Eli Lilly (Axiron), Actavis/Allergan (Androderm), and the successors to Auxilium Pharmaceuticals, whose Endo International parent filed for bankruptcy in 2022.